Weight loss is having a renaissance thanks to Glucagon-like peptide 1 agonists (GLP1s). It’s in the news, on social media, and on reality TV. Patients, healthcare providers, payors, and entrepreneurs are scrambling to understand the science, the opportunity, the cost, and the consequences.